 | |
| Clinical data | |
|---|---|
| Trade names | Wei Ni An |
| Other names | Nylestriol; LY-49825; Ethinylestriol cyclopentyl ether; EE3CPE; 17α-Ethynylestriol 3-cyclopentyl ether |
| Routes of administration | By mouth |
| Drug class | Estrogen;Estrogen ether |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C25H32O3 |
| Molar mass | 380.528 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Nilestriol (INNTooltip International Nonproprietary Name) (brand nameWei Ni An; developmental code nameLY-49825), also known asnylestriol (USANTooltip United States Adopted Name,BANTooltip British Approved Name), is asyntheticestrogen which was patented in 1971[1] and is marketed inChina.[2][3] It is the3-cyclopentylether ofethinylestriol, and is also known asethinylestriol cyclopentyl ether (EE3CPE).[4] Nilestriol is aprodrug of ethinylestriol, and is a morepotent estrogen in comparison.[4] It is described as a slowly-metabolized, long-acting estrogen and derivative ofestriol.[5][6] Nilestriol was assessed in combination withlevonorgestrel for the potential treatment ofpostmenopausalosteoporosis, but this formulation ultimately was not marketed.[7]
 | Thisdrug article relating to thegenito-urinary system is astub. You can help Wikipedia byexpanding it. |
